My major concern is that given CLBP and CHF are significantly...

My major concern is that given CLBP and CHF are significantly larger markets than GVHD, why would Mesoblast pursue GVHD ahead of CLBP and CHF; are the results not as favourable, hence why they have been postponed the read-outs several times (mid-year readout to Q4). You'd think if the results were blockbusters and the results were substantial, they would prioritise such analyses and get the ball rolling on those ones. Also, given the 'sure thing' has had a hiccup, this doesn't incite confidence given the postponing of readouts for the two aforementioned trials. The good thing with CLBP and CHF from what I've observed is that they have a placebo arm which thankfully would make a more compelling argument for approval (though this is debatable with the FDA's concerns for demonstrating MOA through assays).